{'fraction_non_alphanumeric': 0.04093567251461988, 'fraction_numerical': 0.0043859649122807015, 'mean_word_length': 6.061855670103093, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The infusion of anti‐rho‐(D) opsonized erythrocytes may be useful in the treatment of patients, splenectomized or not, with chronic, refractory autoimmune thrombocytopenic purpura—a prospective study

Six patients with chronic refractory autoimmune thrombocytopenic purpura (ATP) were treated with five doses of autologous red blood cells (RBCs) opsonized ex vivo with anti‐RhO‐(D) IgG. Increases in platelet counts were observed in all cases; complete responses requiring no further treatment—for periods of 8–72 months—were recorded in four patients, three of them splenectomized. The cost of the procedure was significantly lower than other 'Fc receptor (FcR) blockade' treatments.